Seikagaku and Ono Announce Positive Study Results

Seikagaku and Ono Pharmaceutical obtained positive topline results from a Phase III confirmatory study of ONO-5704/SI-613 in the treatment of knee osteoarthritis (OA).

ONO-5704/SI-613 is a combination of hyaluronic acid (HA) and an NSAID to address pain and inflammation through a 3-injection regimen. Ono and Seikagaku formed a preliminary...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.

JV

Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.



Contact Us

0